Skip to main content
Top
Published in:

Open Access 01-12-2025 | Type 1 Diabetes | Research

Evaluating cloudcare, a population health management system, in persons with type 1 diabetes: an observational study

Authors: Cornelis A. J. van Beers, Sander Last, Pim Dekker, Erwin Birnie, Nico Riegman, Francisca van der Pluijm, Christine Fransman, Henk J. Veeze, Henk-Jan Aanstoot

Published in: BMC Endocrine Disorders | Issue 1/2025

Login to get access

Abstract

Background

Innovations in diabetes technology have consistently improved outcomes of persons with type1 diabetes (PWDs). However, the volumes of data that these technologies yield require different workflows to alleviate healthcare professionals’ (HCPs) workload and prevent losing relevant data in between visits for interpretation and treatment adaptations. CloudCare is a population health management tool that continuously oversees data from groups of individual PWDs, based on remote monitoring, screening and triaging of individual PWDs. This study assesses the effect of CloudCare on treatment satisfaction of PWDs, HCPs’ workload and glycemic control of PWDs.

Methods

We evaluated the 6-month follow-up outcomes as part of an ongoing prospective cohort study analyzing the effect of CloudCare. Adult PWDs diagnosed > 6 months before inclusion were enrolled. The primary outcome was the change in PWD treatment satisfaction (DTSQc). Secondary outcomes included the number and type of contacts between HCPs and PWDs, diabetes-related distress (PAID-5), and glycemic control.

Results

In September 2024, 175 participants had baseline data available, with a median age of 29.9 years and a median diabetes duration of 17 years. Differences between baseline and 6 months could be calculated for 119 participants. After 6 months follow-up, the median increase in PWDs’ treatment satisfaction (DTSQc) was + 6.0 (IQR 2–11; p < 0.001). The number of face-to-face contacts per PWD per 3 months decreased from 0.85 at baseline to 0.34 (p < 0.001) at 6 months. Diabetes-related distress was significantly decreased at 3 months (p < 0.001) and at 6 months (p = 0.034), compared with baseline. Glucometrics did not significantly change, with a TIR of 79% at baseline and 78% after 6 months (p = 0.39), and a mean glucose management indicator (GMI) of 50 mmol/mol (6.7%) at all timepoints.

Conclusions

In adult PWDs with good glycemic control, CloudCare decreases workload for HCPs, while increasing PWDs’ treatment satisfaction and maintaining excellent glycemic control during 6 months, showing this concept can be applied in modern diabetes care with high density data availability.

Trial registration

Clinicaltrials.gov identifier: NCT05431140; registration date 21-6-2023.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Evaluating cloudcare, a population health management system, in persons with type 1 diabetes: an observational study
Authors
Cornelis A. J. van Beers
Sander Last
Pim Dekker
Erwin Birnie
Nico Riegman
Francisca van der Pluijm
Christine Fransman
Henk J. Veeze
Henk-Jan Aanstoot
Publication date
01-12-2025
Publisher
BioMed Central
Keyword
Type 1 Diabetes
Published in
BMC Endocrine Disorders / Issue 1/2025
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-025-01905-4

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Watch the full video

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more